← Kalshi

When will the FDA approve Intellia Therapeutics' lonvo-z?

Open

Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Selected outcome

Before July 2027

89%

Before July 2027 · 89%

Stored quote · checking the venue

Scheduled end
Jun 30, 2027 ET
Resolution source
U.S. Food and Drug Administration. (opens in a new tab)

Price

Loading price history.

Markets

  • Before July 2027

    When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema?

    89%

    Open · ~$0 24h · ~$4,094 vol

    Bid 87¢ · Ask 91¢

    Open full market view →
  • Before October 2027

    When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema?

    91%

    Open · ~$0 24h · ~$1,000 vol

    Bid 89¢ · Ask 93¢

    Open full market view →
  • Before 2028

    When will the FDA approve Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema?

    91%

    Open · ~$0 24h · ~$629 vol

    Bid 89¢ · Ask 92¢

    Open full market view →
Event statistics
24h vol
~$0
Volume
~$5,723
Liquidity
—
Open int.
3,389 contracts

How this resolves

Scheduled end
Jun 30, 2027 ET
  1. Trading
  2. Closed
  3. In review
  4. Resolved

View on Kalshi